Kisunla™ (donanemab-azbt) – New drug approval
July 2, 2024 - Eli Lilly announced the FDA approval of Kisunla (donanemab-azbt), for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials.